Weak Trigger
now
Submits formal sNDA to the US FDA seeking indication expansion for 'Xpovio' as a 1st-line maintenance therapy for advanced endometrial cancer.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |